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HCT is used as treatment for high risk forms of relapsed
ALL [1–3] and rare subgroups of children and young adults with
primary ALL at very high risk of relapse [4], achieving a DFS
of between 40% and 50% [5,6]. In contrast, the role of HCT as
treatment for ALL in children with DS is unclear. Increased
treatment-related mortality (TRM), mainly due to infection, has
been reported for children with DS-ALL undergoing primary [7]
and relapse therapy [8] as well as HCT [9]. In contrast, two recent
reports suggest leukemic relapse rather than TRM is the main
barrier to successful HCT in childrenwith DS [10,11]. To clarify the
optimal strategy to improve outcomes (reducing treatment intensity
to lower TRM vs. intensification to lower relapse), we reviewed
survival and causes of treatment failure after HCT in a
contemporary, mainly pediatric cohort of patients with DS-ALL.
PATIENTS AND METHODS
Data were obtained from the Center for International Blood and
Marrow Transplant Research (CIBMTR), a working group of more
than 400 transplant centers worldwide that provide detailed patient,
disease, transplant characteristics and outcomes for consecutive
transplantations to a statistical center at the Medical College of
Wisconsin (MCW) or a data-coordinating center at the National
Marrow Donor Program (NMDP). Patients or guardians provide
written informed consent for data submission and research
participation. The Institutional Review Boards of the MCW and
the NMDP approved this study. All patients with ALL and DS who
received allogeneic HCT from an HLA-matched sibling, or a
matched or mismatched unrelated donor between 2000 and 2009
were eligible. ALLwith t(12;21), ETV6-RUNX1 fusion transcript, or
trisomy of chromosomes 4 and 10 were considered low risk; those
with t(9;22),BCR-ABL1 fusion transcript,MLL gene rearrangements
(11q23) or hypodiploidy (<44 chromosomes) high risk and all others
standard risk. Neutrophil recoverywas defined as absolute neutrophil
count (ANC)0.5 109/L for three consecutive measurements;
platelet recovery as a platelet count >20 109/L for 7 days without
transfusion. TRM was defined as any death during remission.
Relapse was defined as morphological recurrence of leukemia at any
site. DFS was defined as survival in continuous complete remission.
We report on 27 patients with Down syndrome (DS) and acute
lymphoblastic leukemia (ALL) who received allogeneic hematopoi-
etic cell transplantation (HCT) between 2000 and 2009. Seventy-
eight percent of patients received myeloablative conditioning and
52% underwent transplantation in second remission. Disease-free
survival (DFS) was 24% at a median of 3 years. Post-transplant
leukemic relapse was more frequent than expected for children with
DS-ALL (54%) than for non-DS ALL. These data suggest leukemic
relapse rather than transplant toxicity is the most important cause of
treatment failure. Advancements in leukemia control are especially
needed for improvement inHCT outcomes for DS-ALL. Pediatr Blood
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Statistical Analysis
The probabilities of neutrophil and platelet recovery, acute and
chronic GVHD, TRM and relapse were calculated using the
cumulative incidence function estimator [12]. For neutrophil and
platelet recovery and GVHD, death without the event was the
competing risk. For TRM, relapse was the competing event and for
relapse, TRM was the competing event. DFS and overall survival
(OS) were calculated using the Kaplan Meier estimator [12].
Ninety-five percent of confidence intervals were calculated using
log transformation. For OS, death from any causewas considered an
event and patients surviving at last follow up were censored. For
DFS, relapse and death were considered events and patients
surviving in remission were censored at last follow up. All P-values
are two-sided and0.05 was considered significant. Analyses were
performed using SAS version 9.1 (Cary, NC).
RESULTS
Between 2000 and 2009, a total of 5,753 allogeneic HCT
procedures were reported to CIBMTR for non-DS-ALL, compared
to 27 for DS-ALL (<1% of all HCT). Patient, disease and transplant
characteristics are shown in Table I. Fifty-five percent of patients
were under 10 years of age at the time of transplantation and 19%
were older than 18 years. Approximately half of all transplantations
occurred in second remission, less than 20% in relapse or refractory
disease. Approximately equal numbers of transplantations occurred
within and after 3 years from the initial ALL diagnosis. For patients
transplanted beyond first remission all patients, except one with an
isolated central nervous system relapse, had a bone marrow relapse.
Seventy-eight percent of recipients received myeloablative con-
ditioning which included total body irradiation (TBI) in all but
two cases. Bone marrow from an HLA-matched sibling was the
predominant graft source. All patients received cyclosporine or
tacrolimus containing GVHD prophylaxis and about a third
received methotrexate (data not shown). The median follow-up
was 3 years (Supplemental Tables I, II).
Outcomes
In univariate analysis, probabilities of hematopoietic recovery,
GVHD and TRM were in keeping with those reported for patients
without DS [6] (Table II). Grade 2–4 acute GVHD [13] developed in
31% of patients by 180 days. Among 8 patients with acute GVHD, 3
TABLE I. Patient, Disease, and Transplant Characteristics
Number (%)
Number of patients 27
Number of centers 21
Age, median (range), years 9 (4–31)
5 years 4
6–10 years 11
11–18 years 7
18–31years 5
Performance score prior to transplantation
100 11
90 5
80 6
50 1
Not reported 4
Disease status prior to transplantation
First complete remission 4
Second complete remission 14
Third complete remission 4
Relapse 4
Primary induction failure 1
Cytogenetics risk group
Intermediate risk 23
Poor risk 3
Not reported 1
Time from diagnosis to HCT, median
(range), months
36 (3–128)
12 months 4
13–36 months 10
>36 months 13
Conditioning regimen
Non-myeloablative/reduced intensity
TBIþ cyclophosphamdieþ fludarabine
(TBI dose: 200 cGy)
2
TBIþ fludarabineþ alemtuzumab (TBI dose:
600 cGy, fractionated)
1
Busulfanþ fludaarbineþ anti-thymocyte globulin 2
Melphalanþ fludarabine 1
Myeloablative
TBIþ cyclophosphamdieþ anti-thymocyte globulin
(TBI dose: 1,320 cGy)
1
TBIþ cyclophosphamdieþ cytarabine
(TBI dose 1,200 cGy)
2
TBIþ cyclophosphamdieþ fludarabibe
(TBI dose: 1,320 cGy)
1
TBIþ cyclophosphamdieþ etoposide
(TBI dose: 1,200 cGy)
1
TBIþ cyclophosphamdieþ thiotepa
(TBI dose: 1,200 cGy)
1
TBIþ cyclophosphamdie (TBI dose: 550 single
fraction N¼ 3 and >1,000 cGy N¼ 5)
8
TBIþ busulfanþ fludarabineþ anti-thymocyte
globulin (TBI 400 cGy, Bu> 9.0mg/kg)
3
TBIþ etoposideþ anti-thymocyte globulin
(TBI dose: 1,200 cGy)
1
TBIþ etoposide (TBI dose: 1,200 cGy) 1
Busulphanþ cyclophosphamdie 1
Busulphanþ fludarabineþ anti-thymocyte
globulin
1
Donor type
HLA-matched sibling 13
Other related 1
8/8 HLA-matched unrelated 6
(Continued )
TABLE I. (Continued)
Number (%)
> 1 HLA-loci mismatched unrelated 7
Graft type
Bone marrow 12
Peripheral blood progenitor cells 7
Umbilical cord blood 8
Year of transplant
2000–2005 11
2006–2009 16
Graft-versus-host disease prophylaxis
Cyclosporine-containing 18
Tacrolimus-containing 9
Median (range) follow-up, months 37 (12–120)
TBI, total body irradiation; HLA, human leukocyte antigen; 8/8,
matched at HLA-A, -B, -C and -DRB1 at the allele-level.
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had grade 2, 3 had grade 3, and 2 had grade 4. Seven patients
developed chronic GVHD (6 limited and 1 extensive). The 3-year
probability of chronic GVHD [14] was 27%. The 3-year cumulative
incidence of TRM was 22%. Among the 6 patients with TRM,
3 patients died from infection, 1 from GVHD, 1 from organ failure,
and the remaining patient from a secondary neoplasm. The
probability of relapse was 54% at 3 years. Consequently, DFS
and OS were low and only 9 of 27 patients with DS-ALL remained
alive and disease-free after HCT. Leukemic relapse was the most
frequent cause of death (11/17, 65%), followed by infection (4/17,
24%) and organ failure (1/17, 6%). Outcomes of patients limited to
those aged 18 years or younger were consistent with the main
analysis (data not shown).
DISCUSSION
Available data on the impact of DS on HCT outcomes for ALL
are derived from small case numbers [15–17], reflect prior
treatment periods [18], and have resulted in conflicting conclu-
sions [9,11]. In 1996, TRM of HCT in 27 children with DS,
including 12 with ALL, was 39% [9] compared to 80% in an earlier
report [18]. Although the feasibility of HCT for children with DS
was stated [9], use of HCT in this group consistently remained lower
than in the non-DS population [8,11,18]. Recently, a report
including eight children with DS-ALL, questioned earlier
conclusions by highlighting that leukemic relapse (5/11, 45%)
rather than TRM (2/11, 18%) was the main barrier to successful
HCT in children with DS [11]. Our analysis of HCT for DS-ALL
extends and confirms the findings of the small case series [11] and is
consistent with HCT outcomes for DS-AML [10]. Relapse is the
predominant cause of treatment failure after HCT in children with
DS limiting DFS and OS (Table II).
Although this report describes the largest cohort to date of
children with DS-ALL undergoing HCT, it is retrospective,
registry-based and thus subject to biases inherent in this form of
patient ascertainment. Like all reports on this topic, ours did not
escape the limits of sample size. Subgroup analyses to assess the
contribution of conditioning regimens and GVHD prophylaxis to
relapse and TRM were not feasible. Despite these limitations our
observations lead us to three suggestions.
First, identification of relapse as main barrier to successful
transplantation cautions against a primary focus on reducing TRM
by choosing minimally intense conditioning. Second, better
leukemia control prior to HCT needs to be achieved while avoiding
the excessive toxicity of conventional ALL chemotherapy in this
group by pursuing agents that target ALL blasts (e.g., via expression
of CD19 and CD22) but lack toxicities of conventional
chemotherapy. Finally, given sample size limitations an interna-
tional collaborative study may be the best option to optimize HCT
protocols for children with DS. In the interim, families and treating
physicians of children with DS-ALL are advised to take into
account realistic estimates of DFS and OS rates after HCT and to
explore new ways of reducing leukemic cell burden prior to HCT to
combat the excess risk of leukemia recurrence.
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TABLE II. Results of Univariate Analysis
Outcomes
Number
events/
evaluable
Probability (95%
confidence
interval)
Neutrophil recovery 24/27
28 days 81% (65–93)
Platelet recovery 22/26
100 days 85% (64–94)
Grade 2–4 acute graft vs. host disease 8/26
100 days 31% (15–49)
180 days 31% (15–49)
Chronic graft vs. host disease 7/26
3 years 27% (12–45)
Transplant-related mortality 6/27
100 days 19% (6–35)
3 years 22% (9–39)
Relapse 12/27
3 years 54% (33–74)
Disease-free survival 18/27
3 years 24% (8–45)
Overall survival 17/27
3 years 29% (12–50)
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